id: NEW:glp1_receptor_agonist_treatment_access_to_alcohol_use_disorder
name: GLP-1 Receptor Agonist Treatment Access â†’ Alcohol Use Disorder
from_node:
  node_id: NEW:glp1_receptor_agonist_treatment_access
  node_name: GLP-1 Receptor Agonist Treatment Access
to_node:
  node_id: alcohol_use_disorder
  node_name: Alcohol Use Disorder
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Systemic administration of GLP-1 receptor agonists allows drug to access receptors in both
  periphery and brain'
- 'Step 2: Central nervous system GLP-1 receptor activation modulates reward pathways and consummatory
  behaviors'
- 'Step 3: Reduced alcohol craving and decreased reward from alcohol consumption'
- 'Step 4: Decreased pathological alcohol consumption patterns characteristic of alcohol use disorder'
evidence:
  quality_rating: B
  n_studies: 3
  primary_citation: Jingchuan Guo et al. 2025. "GLP-1 Receptor Agonists and Research to Treat Overeating
    and Substance Use Disorders.." https://doi.org/10.1523/JNEUROSCI.1375-25.2025
  supporting_citations:
  - Additional citations require full-text access - symposium presentation from 2025 Annual Meeting of
    Society for Neuroscience
  - Human clinical data referenced in abstract
  - Animal model studies referenced in abstract
  doi: 10.1523/JNEUROSCI.1375-25.2025
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: GLP-1 receptor agonists, originally developed for diabetes and obesity, show therapeutic
  potential for alcohol use disorder through central nervous system mechanisms that modulate reward pathways
  and reduce pathological consummatory behaviors.
moderators:
- name: route_of_administration
  direction: strengthens
  strength: moderate
  description: Systemic administration allows access to both peripheral and central nervous system receptors,
    enhancing therapeutic effect on consummatory behaviors
structural_competency:
  equity_implications: This mechanism highlights how pharmaceutical access and healthcare system capacity
    to prescribe emerging treatments represents a structural determinant. Inequitable access to these
    newer, often expensive medications may perpetuate health disparities in AUD treatment. The biological
    mechanism operates through brain reward circuitry rather than individual willpower, supporting a non-stigmatizing
    view of substance use disorders as treatable medical conditions.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.177476'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
